HCII Activators
HCII Activators encompass a diverse group of chemical compounds that interact with the coagulation cascade to enhance the activity of Heparin Cofactor II (HCII). Heparin, a well-known anticoagulant, potentiates the activity of antithrombin III, which subsequently increases the inhibition of thrombin. Since thrombin is an activator of HCII, the presence of heparin ensures that HCII is more effectively utilized in inhibiting additional thrombin molecules. Similarly, dermatan sulfate binds to HCII directly, promoting a conformational change that increases its affinity for thrombin, thus facilitating an accelerated inhibition of the protease.
Compounds such as sodium citrate, argatroban, dabigatran, bivalirudin, and warfarin work by manipulating various aspects of the coagulation pathway to indirectly enhance HCII activity. Sodium citrate chelates calcium ions to prevent coagulation, while argatroban and dabigatran act as direct thrombin inhibitors, maintaining HCII in an active form and able to inhibit more thrombin. Bivalirudin uniquely blocks thrombin by bindingto both the active site and exosite 1. Warfarin, on the other hand, diminishes the synthesis of vitamin K-dependent clotting factors, which leads to a reduction in thrombin generation and thereby prevents the inactivation of HCII. The specificity of these chemical interactions with the coagulation cascade ensures that HCII activity is enhanced due to the reduced competition or inactivation by thrombin.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Heparin | 9005-49-6 | sc-507344 | 25 mg | $119.00 | 1 | |
Heparin binds to antithrombin III and enhances its activity, which in turn accelerates the inhibition of thrombin and other serine proteases in the coagulation pathway. Increased inhibition of thrombin by antithrombin III can enhance the activity of HCII, as thrombin is a known activator of HCII. | ||||||
Citric Acid Trisodium Salt | 68-04-2 | sc-214745 sc-214745A sc-214745B sc-214745C | 100 g 500 g 1 kg 5 kg | $41.00 $61.00 $82.00 $321.00 | ||
Sodium citrate acts as an anticoagulant by chelating calcium ions in the blood, which are essential for coagulation to occur. This alteration in ionic balance can indirectly enhance HCII activity by reducing the amount of thrombin generated. | ||||||
Argatroban | 74863-84-6 | sc-201310 sc-201310A | 10 mg 50 mg | $117.00 $469.00 | 13 | |
Argatroban is a direct thrombin inhibitor that binds to the thrombin active site. Blocking thrombin can indirectly enhance HCII activity by reducing thrombin-mediated inactivation of HCII, allowing HCII to remain active for longer durations. | ||||||
Dabigatran | 211914-51-1 | sc-481166 | 5 mg | $205.00 | 1 | |
Dabigatran, another direct thrombin inhibitor, operates similarly to Argatroban. By inhibiting thrombin, Dabigatran allows for increased HCII activity through sustained availability to inhibit additional thrombin molecules. | ||||||
Bivalirudin | 128270-60-0 | sc-278793 | 5 mg | $110.00 | ||
Bivalirudin directly inhibits thrombin by binding both to the active site and exosite 1. This inhibition contributes to an increase in HCII activity as it prevents thrombin from inactivating HCII. | ||||||
Fondaparinux | 104993-28-4 | sc-507424 | 10 mg | $297.00 | ||
Fondaparinux is a synthetic pentasaccharide that enhances the inhibitory effect of antithrombin on Factor Xa. The reduction of Factor Xa activity can lead to less thrombin generation and thus indirectly enhances HCII activity. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $158.00 | 18 | |
Rivaroxaban is a direct Factor Xa inhibitor, leading to decreased thrombin formation. By reducing the amount of thrombin, Rivaroxaban indirectly enhances the activity of HCII. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $240.00 $634.00 | 2 | |
Apixaban, similar to Rivaroxaban, is also a Factor Xa inhibitor. It works by preventing thrombin generation, which in turn can enhance HCII activity due to less thrombin-mediated inactivation of HCII. | ||||||
Edoxaban | 480449-70-5 | sc-483508 | 25 mg | $522.00 | ||
Edoxaban is a Factor Xa inhibitor that functions to reduce thrombin generation, indirectly enhancing HCII activity through the prevention of HCII inactivation by thrombin. | ||||||
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $73.00 $246.00 | 7 | |
Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, including factors II, VII, IX, and X. By decreasing the levels of these factors, Warfarin indirectly enhances HCII activity by reducing the formation of thrombin, thus preventing HCII inactivation. | ||||||